No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PTN240517C2500
- 0.10
- -0.06-37.50%
15min DelayClose May 10 15:52 ET
0.10High0.10Low
0.10Open0.16Pre Close10 Volume1.06K Open Interest2.50Strike Price100.00Turnover150.59%IV13.54%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.3638Delta0.8413Gamma22.90Leverage Ratio-0.0143Theta0.0001Rho8.33Eff Leverage0.0011Vega
Intraday
- 5D
- 1D
News
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)
Palatin Spikes as FDA Clears Mid-stage Trial for Weight Loss Therapy
Express News | HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 733.33% HC Wainwright & Co. → $17 Reiterates Buy → Buy 02/28/2024 733.33% HC Wainwright & Co. $
Buy Rating Endorsed for Palatin Technologies Amidst Promising Obesity Treatment Advancements
Comments
The co-administration of bremelanotide with tirzepatide represents a novel therapeutic strategy for the treatment of obesity.
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
$Palatin Technologies(PTN.US$ Reuters· 1 min ago
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
1
$Palatin Technologies(PTN.US$
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
1
$Palatin Technologies(PTN.US$
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
1
1
Breakthrough in Dry Eye Disease Treatment: Insights from PL9643 MELODY-1 Phase 3 Trial.
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
1
Read more